But cancers in one of the four groups — called "basal-like" or "triple-negative" breast cancer (TNBC) — have been particularly tricky to treat because they usually don't respond to the "receptor-targeted" treatments that are often effective in treating other types of breast cancer. TNBC tends to be more aggressive than the other types and more likely to recur, and can also have a higher mortality rate.
Fortunately, better drug therapies may be on the horizon. UCLA researchers and collaborators led by Dean Ho, a professor at the UCLA School of Dentistry and co-director of the school's Jane and Jerry Weintraub Center for Reconstructive Biotechnology, have developed a potentially more effective treatment for TNBC that uses nanoscale, diamond-like particles called nanodiamonds.
Nanodiamonds are between 4 and 6 nanometers in diameter and are shaped like tiny soccer balls. Byproducts of conventional mining and refining operations, the particles can form clusters following drug binding and have the ability to precisely deliver cancer drugs to tumors, significantly improving the drugs' desired effect. In the UCLA study, the nanodiamond delivery system has been able to home in on tumor masses in mice with triple negative breast cancer.
Findings from the study are published online April 15 in the peer-reviewed journal Advanced Materials.
"This study demonstrates the versatility of the nanodiamond as a targeted drug-delivery agent to a tumor site," said Ho, who is also a member of the California NanoSystems Institute at UCLA, UCLA's Jonsson Comprehensive Cancer Center and the UCLA Department of Bioengineering. "The agent we've developed reduces the toxic side effects that are associated with treatment and mediates significant reductions in tumor size."
The team combined several important cancer-fighting components on the nanodiamond surface, including Epirubicin, a highly toxic but widely used chemotherapy drug that is often administered in combination with other cancer drugs. The new compound was then bound to a cell-membrane material coated with antibodies that were targeted toward the epidermal growth factor receptor, which is highly concentrated on the surfaces of TNBC cells. The resulting agent is a drug-delivery system called a nanodiamond-lipid hybrid compound, or NDLP.
When tested on mice, the agent was shown to notably decrease tumor growth and eliminate the devastating side effects of cancer treatment.
Because of its toxicity, Epirubicin, when administered alone can cause serious side effects, such as heart failure and reduced white blood cell count, and it has been linked to an increased risk for leukemia. In the study, all of the mice that were given Epirubicin alone died well before the completion of the study. But all the mice given Epirubicin through the targeted NDLPs survived the treatment, and some of the tumors even regressed until they were no longer visible.
"Triple-negative breast cancer is often very aggressive and hard to treat, making aggressive chemotherapy a requirement," said Dr. Edward K. Chow, co-first author of the study and an assistant professor at the Cancer Science Institute of Singapore. "The targeting and therapeutic efficiency of the nanodiamond-lipid agents were quite remarkable. The simultaneous tumor regression and improved drug tolerance are promising indicators for the continued development of the nanodiamonds toward clinical translation."
The research team is now studying the efficacy and safety of the NDLPs in larger animals. Additional research objectives include determining whether nanodiamonds can enhance the tolerance of a wide spectrum of highly toxic drug compounds, which may improve current treatment options and outcomes. These discoveries will serve as precursors for human trials, the researchers said.
"The nanodiamond-lipid hybrid developed in this study is a modular platform," said Laura Moore, a graduate student in Ho's laboratory and a co-first author of the study. "Therefore, we can easily bind a wide spectrum of targeting antibodies and drug compounds to address several diseases."
Dr. No-Hee Park, dean of the UCLA School of Dentistry, noted that the research will provide a foundation for future clinical applications.
"This pioneering study conducted by Dean Ho and his team provides a better understanding of the capabilities of the nanodiamond material to address several diseases," Park said. "Their work is of paramount importance."
Other authors of the study were Professor Eiji Osawa of the NanoCarbon Research Institute in Nagano, Japan, and Professor J. Michael Bishop of UC San Francisco. Laura Moore is currently at Northwestern University.
The study was supported by the National Cancer Institute, the National Science Foundation, the Wallace H. Coulter Foundation, the V Foundation for Cancer Research, the Society for Laboratory Automation and Screening, the George Williams Hooper Foundation, the American Cancer Society, Beckman Coulter, the European Commission, the Cancer Science Institute of Singapore, and the Singapore Ministry of Education Academic Research Fund.
The UCLA School of Dentistry is dedicated to improving the oral and systemic health of the people of California, the nation and the world through its teaching, research, patient care and public service initiatives. The School of Dentistry provides education and training programs that develop leaders in dental education, research, the profession and the community. The School of Dentistry also conducts research programs that generate new knowledge, promote oral health and investigate the cause, prevention, diagnosis and treatment of oral disease in an individualized disease-prevention and management model; and delivers patient-centered oral health care to the community and the state.
For more news, visit the UCLA Newsroom and follow us on Twitter.
Brianna Deane | EurekAlert!
Thanks for the memory: NIST takes a deep look at memristors
22.01.2018 | National Institute of Standards and Technology (NIST)
Let the good tubes roll
19.01.2018 | DOE/Pacific Northwest National Laboratory
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
22.01.2018 | Life Sciences
22.01.2018 | Power and Electrical Engineering
22.01.2018 | Power and Electrical Engineering